The results of this study demonstrated that SIRT5 inhibition significantly impaired the therapeutic response of 6-MP-resistant B-ALL cells to combined treatment with histidine and 6-MP in vitro. Here, SIRT5 is linked to acute lymphoblastic leukemia.